Benzinga
Benzinga
Benzinga
vendredi, septembre 18

CVS Health Corp

CVSNYSE
Trade with Public
Trade with Public
$88.84
-1.43-1.58%
À la clôture: Sep 18, 5:00 PM EST
$89.01
0.170.19%
Après les heures: 5:56 PM EST
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatDividendesComparerOptionsRapport sur les stocks

CVS Health Financials

CVS Health (CVS) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Eli Lilly's Weight-Loss Empire Keeps Expanding As Mounjaro, Zepbound Generate Nearly $15 Billion

Eli Lilly (LLY) beat Q2 earnings expectations & raised 2026 guidance as Mounjaro and Zepbound drove $22.97B in revenue. Read more.
Vandana Singh

CVS Targets Affordable GLP-1 Access With New Eli Lilly Deal

CVS Health beats Q2 earnings expectations and hikes FY26 guidance, but shares fall on profit-taking. Get the full financial breakdown.
Vandana Singh

PRO
CORRECTION: CVS Health Raises FY2026 Adj EPS Guidance from $7.30-$7.50 to $7.90-$8.10 vs $7.45 Est; FY2026 Revenue expected to be more than $414.000B vs $409.235B Est

Benzinga Newsdesk

PRO
CVS Health Raises FY2026 GAAP EPS Guidance from $6.24-$6.44 to $6.84-$7.04 vs $6.12 Est

CVS Health (NYSE:CVS) raises FY2026 GAAP EPS guidance from $6.24-$6.44 to $6.84-$7.04 vs $6.12 analyst estimate..
Benzinga Newsdesk

PRO
CVS Health Q2 Adj. EPS $2.58 Beats $1.85 Estimate, Sales $106.096B Beat $100.114B Estimate

=
Benzinga Newsdesk

These Analysts Increase Their Forecasts On CVS Health After Strong Q1 Results

CVS Health (NYSE:CVS) reported upbeat Q1 earnings & raised 2026 guidance. Analysts have positive outlook with price targets raised.
Avi Kapoor

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved